-
ReShape Lifesciences Inc. (RSLS) Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
-
ReShape Lifesciences Inc. (RSLS) Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
-
ReShape Lifesciences Inc. (RSLS) Prices 1.05M Share Offering at $2.50/sh
-
ReShape Lifesciences Inc. (RSLS) Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
-
ReShape Lifesciences Inc. (RSLS) Tops Q1 EPS by 1898c
-
ReShape Lifesciences Inc. (RSLS) Announces 1:25 Reverse Share Split
-
ReShape Lifesciences Inc. (RSLS) Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device
-
ReShape Lifesciences Inc. (RSLS) Receives Notice of Allowance for U.S. Patent Related to an Intragastric Balloon System
-
ReShape Lifesciences Inc. (RSLS) Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
-
ReShape Lifesciences (RSLS) Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
-
ReShape Lifesciences Inc. (RSLS) Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
-
ReShape Lifesciences (RSLS) Granted Key International Patent in Israel
-
ReShape Lifesciences Inc. (RSLS) Files for 2.11M Share Offering by Selling Stockholders
-
ReShape Lifesciences Inc. (RSLS) Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
-
ReShape Lifesciences Inc. (RSLS) Files for 2.11M Share Offering by Selling Stockholders
-
ReShape Lifesciences Inc. (RSLS) Receives Health Canada Approval for its Next-Generation Lap-Band 2.0 FLEX
-
ReShape Lifesciences Inc. (RSLS) Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems
-
ReShape Lifesciences Inc. (RSLS) Announces 1-for-58 Reverse Stock Split
-
ReShape Lifesciences Inc. (RSLS) Reports Q2 Loss of $0.06/sh
-
ReShape Lifesciences Inc. (RSLS) to Merge with Vyome Therapeutics, Enters Asset Purchase Agreement With Biorad Medisys

